Insmed
INSM
NASDAQ
IPO2000
about INSM
Insmed focuses on developing innovative treatments for rare diseases, primarily advancing its lead product Clazakizumab, a humanized monoclonal antibody targeting immunoglobulin G (IgG) Fc receptors, currently under regulatory review and approved in certain regions for the treatment of immune thrombocytopenic purpura (ITP).
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $162.42 | $164.23 | $159.00 | $34.7B | 463.80K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$1.75 | n/a | 237.78 | -257.13% | -259.95% | 0% |